Cargando…

Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review

Budd-Chiari syndrome is a complex clinical disorder of hepatic venous outflow obstruction, originating from the accessory hepatic vein (HV), large HV, and suprahepatic inferior vena cava (IVC). This disorder includes both HV and IVC obstructions and hepatopathy. This study aimed to conduct a systema...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukhiya, Gauri, Jiao, Dechao, Han, Xinwei, Zhou, Xueliang, Pokhrel, Gaurab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899460/
https://www.ncbi.nlm.nih.gov/pubmed/36751561
http://dx.doi.org/10.25259/JCIS_130_2022
_version_ 1784882641958338560
author Mukhiya, Gauri
Jiao, Dechao
Han, Xinwei
Zhou, Xueliang
Pokhrel, Gaurab
author_facet Mukhiya, Gauri
Jiao, Dechao
Han, Xinwei
Zhou, Xueliang
Pokhrel, Gaurab
author_sort Mukhiya, Gauri
collection PubMed
description Budd-Chiari syndrome is a complex clinical disorder of hepatic venous outflow obstruction, originating from the accessory hepatic vein (HV), large HV, and suprahepatic inferior vena cava (IVC). This disorder includes both HV and IVC obstructions and hepatopathy. This study aimed to conduct a systematic review of the survival rate and clinical success of different types of endovascular treatments for Budd-Chiari syndrome (BCS). All participant studies were retrieved from four databases and selected according to the eligibility criteria for systematic review of patients with BCS. The survival rate, clinical success of endovascular treatments in BCS, and survival rates at 1 and 5 years of publication year were calculated accordingly. A total of 3398 patients underwent an endovascular operation; among them, 93.6% showed clinical improvement after initial endovascular treatment. The median clinical success rates for recanalization, transjugular intrahepatic portosystemic shunt (TIPS), and combined procedures were 51%, 17.50%, and 52.50%, respectively. The median survival rates at 1 and 5 years were 51% and 51% for recanalization, 17.50% and 16% for TIPS, and 52.50% and 49.50% for combined treatment, respectively. Based on the year of publication, the median survival rates at 1 and 5 years were 23.50% and 22.50% before 2000, 41% and 41% in 2000‒2005, 35% and 35% in 2006‒2010, 51% and 48.50% in 2010‒2015, and 56% and 55.50% after 2015, respectively. Our findings indicate that the median survival rate at 1 and 5 years of recanalization treatment is higher than that of TIPS treatment, and recanalization provides better clinical improvement. The publication year findings strongly suggest progressive improvements in interventional endovascular therapy for BCS. Thus, interventional therapy restoring the physiologic hepatic venous outflow of the liver can be considered as the treatment of choice for patients with BCS which is a physiological modification procedure.
format Online
Article
Text
id pubmed-9899460
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Scientific Scholar
record_format MEDLINE/PubMed
spelling pubmed-98994602023-02-06 Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review Mukhiya, Gauri Jiao, Dechao Han, Xinwei Zhou, Xueliang Pokhrel, Gaurab J Clin Imaging Sci Review Article Budd-Chiari syndrome is a complex clinical disorder of hepatic venous outflow obstruction, originating from the accessory hepatic vein (HV), large HV, and suprahepatic inferior vena cava (IVC). This disorder includes both HV and IVC obstructions and hepatopathy. This study aimed to conduct a systematic review of the survival rate and clinical success of different types of endovascular treatments for Budd-Chiari syndrome (BCS). All participant studies were retrieved from four databases and selected according to the eligibility criteria for systematic review of patients with BCS. The survival rate, clinical success of endovascular treatments in BCS, and survival rates at 1 and 5 years of publication year were calculated accordingly. A total of 3398 patients underwent an endovascular operation; among them, 93.6% showed clinical improvement after initial endovascular treatment. The median clinical success rates for recanalization, transjugular intrahepatic portosystemic shunt (TIPS), and combined procedures were 51%, 17.50%, and 52.50%, respectively. The median survival rates at 1 and 5 years were 51% and 51% for recanalization, 17.50% and 16% for TIPS, and 52.50% and 49.50% for combined treatment, respectively. Based on the year of publication, the median survival rates at 1 and 5 years were 23.50% and 22.50% before 2000, 41% and 41% in 2000‒2005, 35% and 35% in 2006‒2010, 51% and 48.50% in 2010‒2015, and 56% and 55.50% after 2015, respectively. Our findings indicate that the median survival rate at 1 and 5 years of recanalization treatment is higher than that of TIPS treatment, and recanalization provides better clinical improvement. The publication year findings strongly suggest progressive improvements in interventional endovascular therapy for BCS. Thus, interventional therapy restoring the physiologic hepatic venous outflow of the liver can be considered as the treatment of choice for patients with BCS which is a physiological modification procedure. Scientific Scholar 2023-01-24 /pmc/articles/PMC9899460/ /pubmed/36751561 http://dx.doi.org/10.25259/JCIS_130_2022 Text en © 2023 Published by Scientific Scholar on behalf of Journal of Clinical Imaging Science https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Review Article
Mukhiya, Gauri
Jiao, Dechao
Han, Xinwei
Zhou, Xueliang
Pokhrel, Gaurab
Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review
title Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review
title_full Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review
title_fullStr Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review
title_full_unstemmed Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review
title_short Survival and clinical success of endovascular intervention in patients with Budd-Chiari syndrome: A systematic review
title_sort survival and clinical success of endovascular intervention in patients with budd-chiari syndrome: a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899460/
https://www.ncbi.nlm.nih.gov/pubmed/36751561
http://dx.doi.org/10.25259/JCIS_130_2022
work_keys_str_mv AT mukhiyagauri survivalandclinicalsuccessofendovascularinterventioninpatientswithbuddchiarisyndromeasystematicreview
AT jiaodechao survivalandclinicalsuccessofendovascularinterventioninpatientswithbuddchiarisyndromeasystematicreview
AT hanxinwei survivalandclinicalsuccessofendovascularinterventioninpatientswithbuddchiarisyndromeasystematicreview
AT zhouxueliang survivalandclinicalsuccessofendovascularinterventioninpatientswithbuddchiarisyndromeasystematicreview
AT pokhrelgaurab survivalandclinicalsuccessofendovascularinterventioninpatientswithbuddchiarisyndromeasystematicreview